25 To 99 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.3)
  • Publication number: 20110212886
    Abstract: The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare. The present invention further relates to pharmaceutical compositions comprising peptides derived from casein in the form of a sterile solution, which compositions are clear and substantially devoid of micelles.
    Type: Application
    Filed: May 13, 2011
    Publication date: September 1, 2011
    Applicants: MILEUTIS LTD., State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization
    Inventors: Jose Mario Iscovich, Nissim Silanikove, Javier Iscovich
  • Publication number: 20110212108
    Abstract: The present invention resides in the discovery that the specific interaction between neuregulin 1 (NRG1) and integrin is important for ErbB signaling, which in turn plays an important role in cellular signaling in various physiological processes such as cell proliferation, especially in cancer cells overexpressing ErbB family members. Thus, this invention provides for a novel method for inhibiting ErbB signaling by using an inhibitor of NRG1-integrin binding. A method for identifying inhibitors of NRG1-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting ErbB signaling.
    Type: Application
    Filed: May 11, 2009
    Publication date: September 1, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Yoshikazu Takada
  • Publication number: 20110212896
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Application
    Filed: September 16, 2010
    Publication date: September 1, 2011
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Patent number: 8007813
    Abstract: The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: August 30, 2011
    Assignees: Apogenix GmbH, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
    Inventor: Henning Walczak
  • Publication number: 20110206752
    Abstract: Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2, its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.
    Type: Application
    Filed: July 24, 2009
    Publication date: August 25, 2011
    Applicants: BCN PEPTIDES, S.A., DIVERDRUGS, S.L.
    Inventors: Cristina Carreno Serraima, Wim Van Den Nest, Antonio Ferrer Montiel, Maria Camprubi Robes, Jimena Fernandez Carneado, Berta Ponsati Obliols
  • Publication number: 20110207677
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc.
    Type: Application
    Filed: June 2, 2009
    Publication date: August 25, 2011
    Inventor: Christophe Bonny
  • Publication number: 20110206723
    Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.
    Type: Application
    Filed: February 24, 2011
    Publication date: August 25, 2011
    Inventors: Per-Åke Albertsson, Charlotte Albertsson-Erlanson
  • Publication number: 20110207678
    Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.
    Type: Application
    Filed: February 7, 2011
    Publication date: August 25, 2011
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: David Naor, Shlomo Nedvetzki, Itshak Golan, Irina Kessel, Lora Melnik
  • Publication number: 20110206674
    Abstract: The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 25, 2011
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Publication number: 20110206760
    Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
    Type: Application
    Filed: July 20, 2009
    Publication date: August 25, 2011
    Applicant: COMPUGEN LTD.
    Inventors: Yossef Kliger, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
  • Patent number: 8003108
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: August 23, 2011
    Assignees: Amgen Inc., UCB SA
    Inventors: Hsieng Sen Lu, Christpher Paszty, Martyn Kim Robinson, Alistair James Henry, Kelly Sue Warmington, John Latham, Alastair Lawson, David Winkler, Aaron George Winters
  • Publication number: 20110201542
    Abstract: Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with oxidative, psychological and/or physical stress, including but not limited to extreme exertion, ischemia, infarct, and damage associated with reperfusion of ischemic or transplanted tissues.
    Type: Application
    Filed: April 27, 2011
    Publication date: August 18, 2011
    Applicant: The Board of Trustees of the University of Illinois
    Inventor: Herve Y. Sroussi
  • Publication number: 20110195911
    Abstract: A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits IFG-R1 activity, as well as a method of inhibiting a IGF1R in a cell, a method of treating or preventing IGF1R-mediated disease, and related compounds, compositions, and methods.
    Type: Application
    Filed: March 27, 2009
    Publication date: August 11, 2011
    Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Nadya I. Tarasova, Sergey G. Tarasov
  • Publication number: 20110195128
    Abstract: Use of glycomacropeptide to treat or prevent gout, use of one or more phospholipids and one or more gangliosides to treat or prevent gout, or use of glycomacropeptide and one or more phospholipids and one or more gangliosides to treat or prevent gout.
    Type: Application
    Filed: October 9, 2009
    Publication date: August 11, 2011
    Inventors: Kay Patricia Palmano, Alastair Kenneth Hugh MacGibbon, Nicole Jane Moore Dalbeth
  • Publication number: 20110195904
    Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: April 5, 2011
    Publication date: August 11, 2011
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Andrew A. YOUNG, Will Vine, Kathryn Prickett, Nigel R.A. Beeley
  • Publication number: 20110195900
    Abstract: Novel peptidic pth receptor agonists and methods of using the same are provided.
    Type: Application
    Filed: August 19, 2009
    Publication date: August 11, 2011
    Applicant: FERRING B.V.
    Inventors: Claudio D. Schteingart, Javier Sueiras-Diaz
  • Patent number: 7994116
    Abstract: The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: August 9, 2011
    Assignee: Pharmasurgics In Sweden AB
    Inventor: Kjell Olmarker
  • Patent number: 7994136
    Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: August 9, 2011
    Assignee: Amgen Inc.
    Inventors: Keith E. Langley, Yves A. DeClerck, Thomas C. Boone
  • Patent number: 7994121
    Abstract: The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: August 9, 2011
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-Sen Lai, David George Sanford
  • Publication number: 20110190223
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Application
    Filed: February 14, 2011
    Publication date: August 4, 2011
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Steven M. Ruben, Craig A. Rosen, Gregory A. Endress
  • Publication number: 20110190210
    Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.
    Type: Application
    Filed: January 27, 2011
    Publication date: August 4, 2011
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Avner ADINI, Robert D'AMATO
  • Publication number: 20110190218
    Abstract: The present invention relates to a polypeptide having antitumor properties, to a vector encoding said polypeptide, to a host cell containing said vector, to uses of said polypeptide in the manufacture of a medicament for the treatment of cancer in patients, to a method comprising binding said polypeptide to molecular chaperones, and to a pharmaceutical composition containing said polypeptide.
    Type: Application
    Filed: July 28, 2009
    Publication date: August 4, 2011
    Applicant: KARLSRUHE INSTITUTE OF TECHNOLOGY
    Inventors: Andrew C. B. Cato, Liubov Shatkina, Katja Jehle, Danilo Maddalo
  • Publication number: 20110189188
    Abstract: Provided is a gp96-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
    Type: Application
    Filed: March 12, 2009
    Publication date: August 4, 2011
    Applicant: COMPUGEN LTD.
    Inventors: Yossef Kliger, Ofer Levy, Itamar Borukhov, Anat Amir, Anat Oren
  • Publication number: 20110190215
    Abstract: The amino acid sequences of peptides are disclosed.
    Type: Application
    Filed: May 15, 2009
    Publication date: August 4, 2011
    Inventor: Marian L. Kruzel
  • Patent number: 7989585
    Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: August 2, 2011
    Assignee: Eli Lilly and Company
    Inventors: Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann
  • Publication number: 20110183922
    Abstract: The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides.
    Type: Application
    Filed: August 14, 2007
    Publication date: July 28, 2011
    Applicant: University of Miami
    Inventor: Richard L. Rotundo
  • Publication number: 20110183921
    Abstract: Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided.
    Type: Application
    Filed: May 17, 2006
    Publication date: July 28, 2011
    Applicant: jojomed GmbH
    Inventor: Nalân Utku
  • Publication number: 20110182921
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Application
    Filed: December 29, 2010
    Publication date: July 28, 2011
    Inventors: Anne DE GROOT, William Martin, Daniel S. Rivera
  • Publication number: 20110183917
    Abstract: The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof.
    Type: Application
    Filed: June 5, 2009
    Publication date: July 28, 2011
    Inventors: Wuyuan Lu, Davide Zella, Min Liu, Changqing Li
  • Publication number: 20110183889
    Abstract: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.
    Type: Application
    Filed: August 28, 2008
    Publication date: July 28, 2011
    Applicant: The Regents of the University of California
    Inventors: Alan M. Fogelman, Mohamad Navab
  • Patent number: 7985736
    Abstract: The present invention relates to compositions to treat CaV2 disorders. The invention also relates to methods treating CaV2 disorders. The invention further relates to kits for treating CaV2 disorders in a subject. The invention further relates to methods of identifying novel treatments for treating Cav2 disorders in a subject.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: July 26, 2011
    Assignee: The John Hopkins University
    Inventors: David T. Yue, Heather L. Agler
  • Patent number: 7985729
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: July 26, 2011
    Assignee: House Research Institute
    Inventors: David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha
  • Publication number: 20110178031
    Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.
    Type: Application
    Filed: March 13, 2009
    Publication date: July 21, 2011
    Applicant: CTI BIO
    Inventors: Jong-Ook Lee, Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim
  • Publication number: 20110178020
    Abstract: Isolated fusion polypeptides are provided that are comprised of a cell-penetrating polypeptide and a SNARE polypeptide aptamer. Further provided are methods for inhibiting neutrophil granule exocytosis that comprise contacting a neutrophil with a fusion polypeptide including a cell-penetrating polypeptide and a SNARE polypeptide aptamer such that the fusion polypeptide enters the neutrophil and inhibits neutrophil granule exocytosis. Also provided are methods for treating a neutrophil-mediated inflammatory disorder by inhibiting SNARE-associated exocytosis in neutrophils.
    Type: Application
    Filed: July 28, 2009
    Publication date: July 21, 2011
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Kenneth R. McLeish, Silvia M. Uriarte, Madhavi J. Rane
  • Publication number: 20110177998
    Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.
    Type: Application
    Filed: July 11, 2008
    Publication date: July 21, 2011
    Inventors: Ronen Shemesh, Zurit Levine, Amir Toporik, Chen Hermesh, Yossef Kliger, Eyal Gofer, Assaf Wool, Dvir Dahary, Yossi Cohen
  • Patent number: 7981861
    Abstract: The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: July 19, 2011
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Thomas R. Coolidge, Mario Ehlers
  • Publication number: 20110171292
    Abstract: The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention.
    Type: Application
    Filed: January 27, 2011
    Publication date: July 14, 2011
    Applicant: The Research Foundation of State University of New York
    Inventors: Basil Rigas, Yu Sun
  • Publication number: 20110172153
    Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.
    Type: Application
    Filed: August 1, 2008
    Publication date: July 14, 2011
    Applicants: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.
    Inventors: Thomas J. Gardella, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
  • Patent number: 7977455
    Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: July 12, 2011
    Assignee: IPSEN Pharma, S.A.S.
    Inventor: Zheng Xin Dong
  • Publication number: 20110165166
    Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.
    Type: Application
    Filed: February 3, 2011
    Publication date: July 7, 2011
    Applicants: Serono Genetics Institute S.A., Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: BERNARD BIHAIN, Lydie Bougueleret, Frances Yen-Potin
  • Publication number: 20110165147
    Abstract: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 1, 2011
    Publication date: July 7, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Inmaculada Silos-Santiago, Joseph M. Carroll, Katherine M. Galvin
  • Publication number: 20110166072
    Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.
    Type: Application
    Filed: February 25, 2011
    Publication date: July 7, 2011
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Mannching Sherry Ku, Yen-Lun Huang
  • Publication number: 20110166061
    Abstract: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
    Type: Application
    Filed: April 26, 2010
    Publication date: July 7, 2011
    Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.
    Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra De Meyer
  • Publication number: 20110166063
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 7, 2011
    Applicant: Nektar Therapeutics
    Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
  • Publication number: 20110165165
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Application
    Filed: December 21, 2010
    Publication date: July 7, 2011
    Applicant: Schering Corporation
    Inventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
  • Patent number: 7972615
    Abstract: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: July 5, 2011
    Assignee: Affinergy, Inc.
    Inventors: Guy Orgambide, Mohmed Anwer, Shrikumar A. Nair, Paul Hamilton
  • Patent number: 7968678
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: June 28, 2011
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Publication number: 20110150980
    Abstract: Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.
    Type: Application
    Filed: November 18, 2010
    Publication date: June 23, 2011
    Applicant: VasoGenix Pharmaceuticals, Inc.
    Inventors: George Lee Southard, Jeffrey Lee Southard
  • Publication number: 20110154522
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Application
    Filed: December 13, 2010
    Publication date: June 23, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Patent number: 7964559
    Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: June 21, 2011
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Carole A. Bewley